RxDoctor Payments Data

Cary Sullivan, DO

Family Medicine · Vian, OKNPI 1497701130

Payments from drug & device makers

$1,378in general payments, 2019–2025

Across 72 payments — averaging $19.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$320
  • Johnson & Johnson$225
  • Lilly USA, LLC$200
  • Exact Sciences$115
  • Novo Nordisk$85
  • GSK$83
  • plus $350 from 9 others

What the payments were for

  • Food & beverage$1,28393%
  • Education$957%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,378 in reported general payments places this provider in the 65th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$189,650
Medicare patients
330
Services billed
2,637

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin85$91,525
EliquisApixaban138$79,917
Trelegy ElliptaFluticasone/Umeclidin/Vilanter74$67,454
OzempicSemaglutide49$52,231
XareltoRivaroxaban70$49,721
TrulicityDulaglutide39$44,903
JanuviaSitagliptin Phosphate32$35,630
MounjaroTirzepatide35$35,039
MyrbetriqMirabegron56$27,111
Breo ElliptaFluticasone/Vilanterol25$19,673
XifaxanRifaximin11$17,663
TradjentaLinagliptin12$13,144
SymbicortBudesonide/Formoterol Fumarate19$9,429
EntrestoSacubitril/Valsartan22$9,275
Spiriva RespimatTiotropium Bromide17$8,798

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$66$113,467114 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$83$90,419111 claims
Lilly USA, LLCTrulicity, Mounjaro$200$79,94274 claims
PfizerEliquis$65$79,917138 claims
Novo NordiskOzempic, Novolog$85$55,10084 claims
Johnson & JohnsonXarelto$225$49,72170 claims
MerckJanuvia$15$35,63032 claims
Astellas Pharma US IncMyrbetriq$320$27,11156 claims
NovartisEntresto$48$9,27522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Vian

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →